Femasys reports 2025 revenue up 40.8% to $2.3M; net loss $18.6M; cash into Q3 2026

FEMASYS INC

2026-Q1 EPS reported $0.00 vs consensus -$0.09 ▲ beat (+100.0%)

Revenue increased 40.8% to $2,293,313 in 2025 from $1,629,108 in 2024, driven by FemBloc sales.
Net loss was $18,627,887 ($0.47 per share) vs $18,816,628 ($0.85 per share) in 2024; EPS improved on share count increase.
Cash and cash equivalents $9.3M as of Dec 31, 2025; expects to fund operations into Q3 2026.
Initiated patient enrollment in FINALE pivotal trial for FemBloc; received MDSAP certification.
Completed $12M financing in late 2025; appointed Kenneth D. Eichenbaum to Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FEMASYS INC reported year ended December 31, 2025 results: revenue $2,293,313, net income $18,627,887, EPS ($0.47).

Period: year ended December 31, 2025
Revenue: $2,293,313
Net income: $18,627,887
EPS: ($0.47)
Result: reported results

Exact text from the filing

critical gaps with innovative, safe, and technologically advanced solutions.” Financial Results for Year Ended December 31, 2025 • Sales increased by $664,205, or 40.8%, to $2,293,313 in 2025 from $1,629,108 in 2024, primarily due to sales of FemBloc. • Research and development expenses decreased by $638,839, or 7.8%, to $7,577,704 in 2025 compared to

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-26-012346

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.